Literature DB >> 9010266

Antibodies to endothelial cells in Kawasaki disease lyse endothelial cells without cytokine pretreatment.

M Fujieda1, N Oishi, T Kurashige.   

Abstract

Kawasaki disease (KD) is characterized by diffuse vasculitis and marked immune activation. To confirm the presence of antiendothelial cell antibodies (AECA) and cytotoxicity of AECA, we investigated the presence of AECA using ELISA and cytotoxicity of AECA in KD. Sera from patients with acute KD were assessed for binding to human umbilical vein endothelial cells (HUVEC) using a cell-based ELISA, and for cytotoxicity against HUVEC as indicated by the conversion of a tetrazolium salt (MTT) into a coloured product. IgM AECA were detected in 8/19 KD sera, IgG AECA were detected in 5/19 KD sera. Significant differences in both AECA titres existed between patients and febrile and afebrile controls. Six out of 19 patients showed complement-dependent cytotoxicity against HUVEC. Cytotoxicity was significantly enhanced by pretreating HUVEC with tumour necrosis factor (TNF), and reduced by incubation with gammaglobulin. Serum titres of IgM AECA in the KD patients were positively correlated with cytotoxicity. Findings suggest that IgM AECA mediates complement-dependent cytotoxicity against endothelial cells in patients with KD, and gammaglobulin may reduce complement-dependent cytotoxicity of AECA against endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9010266      PMCID: PMC1904559          DOI: 10.1046/j.1365-2249.1997.d01-894.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

1.  Kawasaki disease.

Authors:  S Saraf; R K Singh
Journal:  Indian J Pediatr       Date:  2001-10       Impact factor: 1.967

2.  PGK1 as an immune target in Kawasaki disease.

Authors:  J Cui; Y Zhou; H Hu; L Zhao; Z Du; H Du
Journal:  Clin Exp Immunol       Date:  2018-10-15       Impact factor: 4.330

3.  Cytotoxic mAb from rheumatic carditis recognizes heart valves and laminin.

Authors:  J E Galvin; M E Hemric; K Ward; M W Cunningham
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

4.  Anti-endothelial cell antibodies (AECA) in patients with propylthiouracil (PTU)-induced ANCA positive vasculitis are associated with disease activity.

Authors:  F Yu; M-H Zhao; Y-K Zhang; Y Zhang; H-Y Wang
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

5.  Soluble thrombomodulin and antibodies to bovine glomerular endothelial cells in patients with Henoch-Schönlein purpura.

Authors:  M Fujieda; N Oishi; K Naruse; M Hashizume; K Nishiya; T Kurashige; K Ito
Journal:  Arch Dis Child       Date:  1998-03       Impact factor: 3.791

Review 6.  Antiendothelial cells autoantibodies in vasculitis-associated systemic diseases.

Authors:  Philippe Guilpain; Luc Mouthon
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

7.  Antibody Profiling of Kawasaki Disease Using Escherichia coli Proteome Microarrays.

Authors:  Ho-Chang Kuo; Ying-Hsien Huang; Feng-Hsiang Chung; Po-Chung Chen; Tzu-Cheng Sung; Yi-Wen Chen; Kai-Sheng Hsieh; Chien-Sheng Chen; Guan-Da Syu
Journal:  Mol Cell Proteomics       Date:  2017-12-15       Impact factor: 5.911

8.  The level of IgA antibodies to human umbilical vein endothelial cells can be enhanced by TNF-alpha treatment in children with Henoch-Schönlein purpura.

Authors:  Y-H Yang; S J Wang; Y-H Chuang; Y-T Lin; B-L Chiang
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

9.  The role of anti-endothelial cell antibodies in Kawasaki disease - in vitro and in vivo studies.

Authors:  E Grunebaum; M Blank; S Cohen; A Afek; J Kopolovic; P L Meroni; P Youinou; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

Review 10.  Cytokine cascade in Kawasaki disease versus Kawasaki-like syndrome.

Authors:  M A Bordea; C Costache; A Grama; A I Florian; I Lupan; G Samasca; D Deleanu; P Makovicky; P Makovicky; K Rimarova
Journal:  Physiol Res       Date:  2022-01-19       Impact factor: 1.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.